Prisma Health Fellowship in Urologic Oncology

@daviesbj Plaque is protected. Patina.

Brushing teeth before my dentist appointment so she doesn't notice I havent flossed in a decade. Surely this will work

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc

Just published online in @JCO_ASCO : #SunRISe1 Phase IIb results show TAR-200 (novel intravesical drug releasing system) achieves 82.4% CR in BCG-unresponsive high-risk NMIBC—with durable responses (median DOR 25.8 mo) & low toxicity. A game-changer for pts with #NMIBC. @AndreaNecchi @USC_Urology @IBCG_BladderCA @BladderCaJrnl @JoeJacobMD1 @DrFelixGuerrero @griffoncanisius @dzainfeld @evanguelosx @KSMurrayUro @Sweiti @DocBladder @UroDocAsh @BladderCancerUS 🔗 doi.org/10.1200/JCO-25…

FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC businesswire.com/news/home/2025… @UroGenPharma @UrogerliMD @siadaneshmand @MaxKates @IBCG_BladderCA @joanfundi

Just completed the first FANS ureteroscopy at @PH_Surgery using the @DornierMedTech Hoover suction access sheath. A true game changer for the management of kidney stones!

Bladder cancer care is evolving fast! From NMIBC to mUC, learn more with Drs. Sia Daneshmand (@siadaneshmand), Laura Bukavina (@laurabukavinamd), Matthew D. Galsky (@MattGalsky), & Sarah P. Psutka, MD, MS, FACS (@spsutkaMD)! bit.ly/3FnjP23 @PeerView

We need to be thoughtful about what our patients want and counsel them well so they make the best decision possible!! Especially in the era of ever improvements in bladder sparing efficacy…. This data is super valuable

#Crossfire: Controversies in #Urology: double intravesical chemotherapy is preferred over new FDA-approved agents for BCG unresponsive #NMIBC: the price of success. #AUA25 written coverage by @chavarriagaj @UofT > bit.ly/3EJ1Fr7 @Tullika_Garg @ctleeuro @VigneshPackiam @AmerUrological

LVI is tough. With our improved management and therapies I am generally aggressive in promoting bladder sparing for NMIBC - but this gives pause: T1 with LVI had higher node positivity rates than MIBC without LVI, at least in NCDB 2004-2014.. Need large granular series that include more variables (blue light, presence of LVI at re-TURBT) and contemporary agents (especially immune) to get more answers pubmed.ncbi.nlm.nih.gov/30297221/

Editor's Choice: Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial by Agne Krilaviciute et al Read the full article here: buff.ly/49AgLdA Come back later to read the Editorial! #UroSoMe #MedTwitter #eururol #editorschoice #highlightarticle #ProstateCancer #PCa #Spotlight @GGiannarini

🚨 Promising alternative to BCG for #NMIBC! Drs. @SHPatelMD1 & @MaxKates @brady_urology sit down with @UroCancerMD @VUMCurology to discuss phase II trial results: 100% complete response at 3 months & 92% at 12 months with gemcitabine + docetaxel. Key takeaways: combination therapy logistics, maintenance strategies, & BCG shortage solutions. #WatchNow > bit.ly/40rd1Ih @urogabe

END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI nejm.org/doi/full/10.10…

@prisma_uroonc fellow Nick Noble giving an update on high impact bladder cancer articles of 2024. @UroOnc @RyanWerntzMD

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

Robot-assisted Radical Cystectomy with IUD Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomized Controlled Trial Confirms: similar outcomes, shorter OR time with ORC, lower EBL with RARC europeanurology.com/article/S0302-… #BladderCancer

2/After 50 years of adjuvant trials on RCC (3 slides); #KEYNOTE564 demonstrates overall survival (OS) benefit!

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

@Agarwal_CaB @UroDocAsh @joanfundi What’s interesting is we have started to experiment with ctcs with comp like signatera. example of this is we had pt with nac. Post nac signatera elevated. Then rc with lnd. N1. Post rc signatera 0. Unclear what this means,prospective follow up correlating recurrence needed

@UroDocAsh @joanfundi In my mind, these trials refute traditional Halstedian dogma that “more is better” for a lymph node dissection in bladder cancer. However, it is important to realize that a lymph node dissection is not obsolete!

Our collaborative review on LND in GU cancers; tremendous effort by @AmandaMyersMD @MDAndersonNews #OncSurgery @EurUrolOncol Open Access link: authors.elsevier.com/a/1i6Q09Cfv-xp… @Albert0Briganti @BradLeibovichMD #SethLerner @UroMoschini @MRoupret @DrShariat @SpiessPhilippe @Astenzl @Tanejauro @TouijerKarim